세계의 착상전 유전자 진단 시장 규모 조사 : 검사 유형별, 지역별, 예측(2022-2032년)

Global Preimplantation Genetic Diagnosis Market is valued at approximately USD 72.12 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.41% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is a sophisticated reproductive technology used with In Vitro Fertilization (IVF) to screen embryos for genetic conditions before implantation. This process helps couples at risk of passing on inherited genetic disorders increase their chances of having a healthy child. The IVF process involves hormonal treatments, egg retrieval, fertilization in a lab, and embryo culture to the blastocyst stage, where cells are biopsied and analyzed for genetic abnormalities. Embryos without defects are selected for transfer into the uterus. PGD reduces the transmission of genetic disorders, increases IVF success rates, and raises ethical considerations. It is beneficial for couples with a family history of genetic disorders, recurrent miscarriages, or fertility issues. The Global Preimplantation Genetic Diagnosis Market is growing due to increasing awareness of genetic disorders, advancements in reproductive technologies, rising acceptance of IVF procedures, and supportive government regulations. The trend of delayed parenthood and rising infertility rates also contribute to the demand for PGD, driving market growth.

The Global Preimplantation Genetic Diagnosis (PGD) market is driven by increasing awareness of genetic disorders, advancements in reproductive technologies, rising prevalence of inherited conditions, and growing acceptance of IVF procedures. Technological innovations, such as next-generation sequencing, have improved PGD's accuracy and efficiency, enabling broader detection of genetic abnormalities and reducing implantation failure and miscarriage risks. These advancements make PGD more reliable and accessible, encouraging more couples to use this technology for healthier offspring. However, high costs, ethical concerns regarding embryo selection, and the psychological impact on parents are significant barriers. Additionally, limited access to advanced reproductive technologies in developing regions and varying legal and ethical guidelines across countries pose challenges. Despite these, the supportive government regulations and funding for genetic research contribute to market growth, making PGD a valuable tool for ensuring the health of future generations.

The key regions considered for the Global Preimplantation Genetic Diagnosis market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the dominating region in terms of revenue in the Global Preimplantation Genetic Diagnosis (PGD) Market. The region boasts advanced healthcare infrastructure, allowing for widespread access to cutting-edge reproductive technologies. High adoption rates of PGD and IVF procedures are driven by increasing awareness of genetic disorders and the benefits of early genetic screening among prospective parents. Significant investments in research and development, coupled with supportive government policies and funding, foster continuous innovation and improvement in genetic testing methods. The presence of leading biotechnology companies and top-tier fertility clinics further enhances North America's market position. On the other hand, the market in Asia Pacific is expected to develop at the fastest rate over the forecast period.

Major market players included in this report are:

• Natera Inc.
• Agilent Technologies, Inc.
• Reproductive Genetic Innovations, LLC
• PerkinElmer, Inc.
• Pacgenomics Inc
• Quest Diagnostics Inc.
• Laboratory Corporation of America Holdings,
• Cegat Gmbh
• Invitae Corp.
• Illumina Inc.

The detailed segments and sub-segments of the market are explained below:

By Test Type

• Chromosomal Abnormalities
• Aneuploidy
• X-linked diseases
• Single Gene Disorders
• HLA Typing
• Gender selection
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Preimplantation Genetic Diagnosis Market Definition and Research Assumptions

• 1.1. Research Objective
• 1.2. Market Definition
• 1.3. Research Assumptions
  • 1.3.1. Inclusion & Exclusion
  • 1.3.2. Limitations
  • 1.3.3. Supply Side Analysis
    • 1.3.3.1. Availability
    • 1.3.3.2. Infrastructure
    • 1.3.3.3. Regulatory Environment
    • 1.3.3.4. Market Competition
    • 1.3.3.5. Economic Viability (Consumer's Perspective)
  • 1.3.4. Demand Side Analysis
    • 1.3.4.1. Regulatory frameworks
    • 1.3.4.2. Technological Advancements
    • 1.3.4.3. Environmental Considerations
    • 1.3.4.4. Consumer Awareness & Acceptance
• 1.4. Estimation Methodology
• 1.5. Years Considered for the Study
• 1.6. Currency Conversion Rates

Chapter 2. Executive Summary

• 2.1. Global Preimplantation Genetic Diagnosis Market Size & Forecast (2022- 2032)
• 2.2. Regional Summary
• 2.3. Segmental Summary
  • 2.3.1. By Test Type
• 2.4. Key Trends
• 2.5. Recession Impact
• 2.6. Analyst Recommendation & Conclusion

Chapter 3. Global Preimplantation Genetic Diagnosis Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Challenges
• 3.3. Market Opportunities

Chapter 4. Global Preimplantation Genetic Diagnosis Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Preimplantation Genetic Diagnosis Market Size & Forecasts by Test Type 2022-2032

• 5.1. Chromosomal Abnormalities
• 5.2. Aneuploidy
• 5.3. X-linked diseases
• 5.4. Single Gene Disorders
• 5.5. HLA Typing
• 5.6. Gender selection
• 5.7. Others

Chapter 6. Global Preimplantation Genetic Diagnosis Market Size & Forecasts by Region 2022-2032

• 6.1. North America Preimplantation Genetic Diagnosis Market
  • 6.1.1. U.S. Preimplantation Genetic Diagnosis Market
    • 6.1.1.1. Test Type breakdown size & forecasts, 2022-2032
  • 6.1.2. Canada Preimplantation Genetic Diagnosis Market
• 6.2. Europe Preimplantation Genetic Diagnosis Market
  • 6.2.1. U.K. Preimplantation Genetic Diagnosis Market
  • 6.2.2. Germany Preimplantation Genetic Diagnosis Market
  • 6.2.3. France Preimplantation Genetic Diagnosis Market
  • 6.2.4. Spain Preimplantation Genetic Diagnosis Market
  • 6.2.5. Italy Preimplantation Genetic Diagnosis Market
  • 6.2.6. Rest of Europe Preimplantation Genetic Diagnosis Market
• 6.3. Asia-Pacific Preimplantation Genetic Diagnosis Market
  • 6.3.1. China Preimplantation Genetic Diagnosis Market
  • 6.3.2. India Preimplantation Genetic Diagnosis Market
  • 6.3.3. Japan Preimplantation Genetic Diagnosis Market
  • 6.3.4. Australia Preimplantation Genetic Diagnosis Market
  • 6.3.5. South Korea Preimplantation Genetic Diagnosis Market
  • 6.3.6. Rest of Asia Pacific Preimplantation Genetic Diagnosis Market
• 6.4. Latin America Preimplantation Genetic Diagnosis Market
  • 6.4.1. Brazil Preimplantation Genetic Diagnosis Market
  • 6.4.2. Mexico Preimplantation Genetic Diagnosis Market
  • 6.4.3. Rest of Latin America Preimplantation Genetic Diagnosis Market
• 6.5. Middle East & Africa Preimplantation Genetic Diagnosis Market
  • 6.5.1. Saudi Arabia Preimplantation Genetic Diagnosis Market
  • 6.5.2. South Africa Preimplantation Genetic Diagnosis Market
  • 6.5.3. Rest of Middle East & Africa Preimplantation Genetic Diagnosis Market

Chapter 7. Competitive Intelligence

• 7.1. Key Company SWOT Analysis
• 7.2. Top Market Strategies
• 7.3. Company Profiles
  • 7.3.1. Natera Inc.
    • 7.3.1.1. Key Information
    • 7.3.1.2. Overview
    • 7.3.1.3. Financial (Subject to Data Availability)
    • 7.3.1.4. Product Summary
    • 7.3.1.5. Market Strategies
  • 7.3.2. Agilent Technologies, Inc.
  • 7.3.3. Reproductive Genetic Innovations, LLC
  • 7.3.4. PerkinElmer, Inc.
  • 7.3.5. Pacgenomics Inc
  • 7.3.6. Quest Diagnostics Inc.
  • 7.3.7. Laboratory Corporation of America Holdings
  • 7.3.8. Cegat Gmbh
  • 7.3.9. Invitae Corp.
  • 7.3.10. Illumina Inc.

Chapter 8. Research Process

• 8.1. Research Process
  • 8.1.1. Data Mining
  • 8.1.2. Analysis
  • 8.1.3. Market Estimation
  • 8.1.4. Validation
  • 8.1.5. Publishing
• 8.2. Research Attributes